載入中
Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating advanced, programmed cellular immunotherapies. These innovative treatments are designed to combat cancer and various immune disorders across the globe. A significant portion of its development pipeline concentrates on NK- and T-cell immuno-oncology programs. Key candidates include FT516, which targets acute myeloid leukemia (AML), B-cell lymphoma, and advanced solid tumors; FT596 for B-cell lymphoma and chronic lymphocytic leukemia; FT538, addressing AML and multiple myeloma; FT576, also focused on multiple myeloma; FT819, aimed at both hematologic malignancies and solid tumors; FT536, another program for solid tumors; and FT500, intended for advanced solid tumors. The company also actively engages in strategic collaborations to advance its research and development. It holds an agreement with Ono Pharmaceutical Co. Ltd. for the joint development and commercialization of two novel, "off-the-shelf" iPSC-derived CAR T-cell therapies. Furthermore, Fate Therapeutics maintains a research collaboration and licensing deal with Juno Therapeutics, Inc., focusing on identifying small molecule modulators that can enhance the therapeutic efficacy of genetically engineered T-cell immunotherapies. A separate collaboration and option agreement exists with Janssen Biotech, Inc. Established in 2007, Fate Therapeutics, Inc. is based in San Diego, California.
一般交易時段
US$2.055
−US$0.075 · -3.52%
盤中時間採用ET。市場資料可能有所延遲。
Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating advanced, programmed cellular immunotherapies. These innovative treatments are designed to combat cancer and various immune disorders across the globe. A significant portion of its development pipeline concentrates on NK- and T-cell immuno-oncology programs. Key candidates include FT516, which targets acute myeloid leukemia (AML), B-cell lymphoma, and advanced solid tumors; FT596 for B-cell lymphoma and chronic lymphocytic leukemia; FT538, addressing AML and multiple myeloma; FT576, also focused on multiple myeloma; FT819, aimed at both hematologic malignancies and solid tumors; FT536, another program for solid tumors; and FT500, intended for advanced solid tumors. The company also actively engages in strategic collaborations to advance its research and development. It holds an agreement with Ono Pharmaceutical Co. Ltd. for the joint development and commercialization of two novel, "off-the-shelf" iPSC-derived CAR T-cell therapies. Furthermore, Fate Therapeutics maintains a research collaboration and licensing deal with Juno Therapeutics, Inc., focusing on identifying small molecule modulators that can enhance the therapeutic efficacy of genetically engineered T-cell immunotherapies. A separate collaboration and option agreement exists with Janssen Biotech, Inc. Established in 2007, Fate Therapeutics, Inc. is based in San Diego, California.
日內區間
目前US$2.055
52週區間
目前US$2.055
盤中時間採用ET。市場資料可能有所延遲。
Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating advanced, programmed cellular immunotherapies. These innovative treatments are designed to combat cancer and various immune disorders across the globe. A significant portion of its development pipeline concentrates on NK- and T-cell immuno-oncology programs. Key candidates include FT516, which targets acute myeloid leukemia (AML), B-cell lymphoma, and advanced solid tumors; FT596 for B-cell lymphoma and chronic lymphocytic leukemia; FT538, addressing AML and multiple myeloma; FT576, also focused on multiple myeloma; FT819, aimed at both hematologic malignancies and solid tumors; FT536, another program for solid tumors; and FT500, intended for advanced solid tumors. The company also actively engages in strategic collaborations to advance its research and development. It holds an agreement with Ono Pharmaceutical Co. Ltd. for the joint development and commercialization of two novel, "off-the-shelf" iPSC-derived CAR T-cell therapies. Furthermore, Fate Therapeutics maintains a research collaboration and licensing deal with Juno Therapeutics, Inc., focusing on identifying small molecule modulators that can enhance the therapeutic efficacy of genetically engineered T-cell immunotherapies. A separate collaboration and option agreement exists with Janssen Biotech, Inc. Established in 2007, Fate Therapeutics, Inc. is based in San Diego, California.
日內區間
目前US$2.055
52週區間
目前US$2.055
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 664.6萬 USD | 1363.1萬 USD | 6353.3萬 USD | 9630萬 USD | 5584.6萬 USD |
| 銷貨成本 | 1290.1萬 USD | 1.19億 USD | 1.57億 USD | 1375.8萬 USD | 585萬 USD |
| 毛利 | −625.5萬 USD | −1.05億 USD | −9365.4萬 USD | 8254.2萬 USD | 4999.6萬 USD |
| 研究與開發 | 1.08億 USD | 1.35億 USD | 1.73億 USD | 3.2億 USD | 2.16億 USD |
| 銷售、一般及管理費用 | 4652.1萬 USD | 9063.9萬 USD | 9685.7萬 USD | 8423.2萬 USD | 5732.1萬 USD |
| 營業費用 | 1.41億 USD | 1.05億 USD | 9685.7萬 USD | 3.91億 USD | 2.67億 USD |
| 利息收入 | 1105.2萬 USD | 1728.8萬 USD | 1718.6萬 USD | 584.2萬 USD | 130.9萬 USD |
| 折舊和攤銷 | 929.5萬 USD | 1896.2萬 USD | 1828.2萬 USD | 1375.8萬 USD | 585萬 USD |
| 營業利益 | −1.48億 USD | −2.1億 USD | −1.91億 USD | −3.08億 USD | −2.17億 USD |
| 淨利 | −1.36億 USD | −1.86億 USD | −1.61億 USD | −2.82億 USD | −2.12億 USD |
公司資料更新於 2026年10月13日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$5.63
上漲空間 173.97%報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI763.46萬0.00%2.3兆 USD0.03%US$380.94-0.17%
Vanguard Extended Market ETFVXF286.76萬0.00%954億 USD0.05%US$232.13-0.60%
Schwab U.S. Small-Cap ETFSCHA117.13萬0.01%217.13億 USD0.03%US$32.505-0.47%
iShares Micro-Cap ETFIWC76.43萬0.06%13.17億 USD0.60%US$180.27-0.77%
Vanguard Health Care ETFVHT67.94萬0.00%220億 USD0.09%US$317.13-1.10%
Invesco RAFI US 1500 Small-Mid ETFPRFZ52.99萬0.02%26.7億 USD0.36%US$52.74-0.34%
EA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSM39萬0.33%1.16億 USD0.73%US$15.71-0.87%
Avantis U.S. Small Cap Equity ETFAVSC32.21萬0.01%30.79億 USD0.25%US$69.87-0.14%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFSchwab U.S. Small-Cap ETFSCHAiShares Micro-Cap ETFIWCVanguard Health Care ETFVHTInvesco RAFI US 1500 Small-Mid ETFPRFZEA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSMAvantis U.S. Small Cap Equity ETFAVSCAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
